Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: ARIAD Pharmaceuticals
So what: A day after shares popped, the company announced a stock offering at $3.70 per share. The company will sell 16 million shares and net $59.2 million before fees.
Now what: The cash will be used to fund a trial of oral ponatinib, which the company hopes to bring to the market. This is disappointing after yesterday's bump, but the offering will provide enough cash to fund operations into 2012. I am more cautious about this news today because the offer price was lower than yesterday's close and dilutes current shareholders.
Interested in more info on ARIAD Pharmaceuticals? Add it to your watchlist by clicking here.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings, or follow his Motley Fool CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.